Status:
COMPLETED
Temperament Dimensions and Awakening Salivary Cortisol Levels in ADHD.
Lead Sponsor:
Università degli Studi di Sassari
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
3-16 years
Brief Summary
To analyze heterogeneity in ADHD experts in last decade advised to look beyond the lists of existing symptoms towards phenotypic measures that can be represented dimensionally and have well-theorized ...
Detailed Description
Recently evidence suggests that measures of child temperament may predict ADHD symptoms (Einziger et al., 2018). Temperament is a characteristic of personality (Buss \& Plomin, 1984; Crowell, 2016) an...
Eligibility Criteria
Inclusion
- ADHD group:
- The assessment was completed as part of their routine psychiatric assessment using unstructured interview, screening of ADHD and other psychiatric symptoms through parent questionnaires, and direct observation with the participants, which led to a DSM-5-based diagnosis of ADHD;
- Signed informed consent from parents or legal guardian and/or assent for youth aged \>12 y/o.
- TDY (Typically Developing Control) - group:
- Signed informed consent from parents or legal guardian and/or assent for youth aged \>12 y/o;
- TDY were recruited from pre-school, primary and secondary schools in the local catchment area.
- Assessment of the TDY was carried out by a clinician in schools through an unstructured interview with the parents and teachers.
Exclusion
- ADHD group:
- Not signed informed consent from parents or legal guardian and/or assent for youth aged \>12 y/o;
- IQ below 70;
- neurological and other psychiatric disorders;
- genetic and/or medical conditions mimicking ADHD symptoms;
- treatment with psychotropic medications other than ADHD medications;
- TDY were also excluded if they presented with any learning or behavioural difficulties as reported in the parent and teacher interviews, as well as mild, moderate or severe symptoms of ADHD in the clinician-led rating scale.
- TDY (Typically Developing Control) - group:
- Not signed informed consent from parents or legal guardian and/or assent for youth aged \>12 y/o;
- IQ below 70;
- neurological and other psychiatric disorders;
- genetic and/or medical conditions mimicking ADHD symptoms;
- treatment with psychotropic medications other than ADHD medications.
Key Trial Info
Start Date :
January 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 12 2018
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04326543
Start Date
January 18 2017
End Date
January 12 2018
Last Update
March 30 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Alessandra Carta
Sassari, Italy, 07100
2
Complex Operating Unit of Child and Adolescent Neuropsychiatry - University of Sassari
Sassari, Italy, 07100